Previous close | 0.1400 |
Open | 0.1402 |
Bid | 0.1352 x 1300 |
Ask | 0.1404 x 900 |
Day's range | 0.1350 - 0.1435 |
52-week range | 0.1340 - 1.6400 |
Volume | |
Avg. volume | 767,382 |
Market cap | 8.841M |
Beta (5Y monthly) | 1.75 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.7600 |
Earnings date | 02 Aug 2023 - 07 Aug 2023 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 3.12 |
Aeglea BioTherapeutics ( NASDAQ:AGLE ) First Quarter 2023 Results Key Financial Results Net loss: US$18.4m (loss...
Aeglea (AGLE) delivered earnings and revenue surprises of -5.26% and 16.47%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) today announced financial results for the first quarter 2023.
Aeglea BioTherapeutics (AGLE) announces failure to meet goals in the phase I/II study of pegtarviliase for the treatment of Classical Homocystinuria. The stock is down 26% following the news.
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing human enzyme therapeutics to benefit people with rare metabolic diseases, today announced interim results from the ongoing Phase 1/2 clinical trial of pegtarviliase, a novel recombinant human enzyme engineered to reduce elevated levels of total homocysteine, for the treatment of Classical Homocystinuria. Following its review of the interim results, the company announced that it is exploring strategic al
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the company granted non-qualified equity awards to four new employees with a grant date of March 17, 2023, as equity inducement awards outside of the company's 2016 Equity Incentive Plan, but under the terms of the company's 2018 Equity Inducement Plan. The awards were granted as material i
Aeglea (AGLE) delivered earnings and revenue surprises of 10% and 1.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2022, and provided program updates.
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced an update to its corporate structure. These changes are in addition to the restructuring process that was initiated in August 2022 and are intended to further streamline the organization, create operational efficiencies to support near- and long-term objectives and maximize the value of the
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Aeglea (AGLE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that the compensation committee of its board of directors has granted non-qualified stock options to purchase an aggregate of 1,884,838 shares of Aeglea's common stock to Jeffrey M. Goldberg as a material inducement to his appointment as the chief executive officer of Aeglea in accordance w
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Jeffrey M. Goldberg as president, chief executive officer and member of the board of directors effective November 29, 2022. Mr. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercializatio
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that Linda Neuman, M.D., M.B.A. has been appointed chief medical officer. Dr. Neuman's appointment is an internal promotion from her previous role as Aeglea's senior vice president of clinical development.
Aeglea (AGLE) delivered earnings and revenue surprises of 20.83% and 72.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the third quarter ended September 30, 2022 and provided program updates.
Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression platform to develop treatments for blood cancers.
AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that it will host a key opinion leader (KOL) webinar on Classical Homocystinuria, and Aeglea's potential treatment and lead clinical asset pegtarviliase on Thursday, October 27, 2022 at 10:00 AM Eastern Time.
NeuBase (NBSE) intends to reduce its existing workforce by nearly 60%. The company plans to maximize shareholder value and focus on the advancement of its platform in gene editing. Stock up.
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that dosing in the third cohort of the Phase 1/2 clinical trial of pegtarviliase for the treatment of Classical Homocystinuria is underway. Patients in this cohort are receiving 1.35 mg/kg of pegtarviliase once weekly administered via subcutaneous injection; patients in cohorts 1 and 2 rece
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced oral and poster presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022 being held in Freiburg, Germany August 30 – September 2. The presentations include perspectives on dietary management of Homocystinuria, which will be given as both an oral an
Whilst it may not be a huge deal, we thought it was good to see that Marcio De'Souza, who is a company insider...
Aeglea (AGLE) announces a corporate restructuring plan to prioritize the development of AGLE-177 for patients living with homocystinuria. The company's current CEO resigns. Stock down.